Insulet Corporation
PODDHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Insulet Corporation (PODD) is listed under Medical Devices. The company carries a $10.33B market cap, placing it firmly in the large-cap category. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Market Cap
$10.33B
Beta
1.10
P/E (TTM)
27.90
P/E (Fwd)
19.30
EPS (TTM)
$5.34
EPS (Fwd)
$7.72
ROE
26.0%
ROA
9.7%
Cash
$534.9M
Total Debt
$948.4M
Free CF
$236.9M
52W Change
-54.3%
Annual Financials
Cash vs Debt
Where PODD stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, PODD finished 18.58% below its 150-day moving average ($165.16) and 29.33% below its 200-day moving average ($190.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PODD overbought or oversold?
At the October 9, 2026 close, PODD's RSI(14) was 32.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $534.9M in cash, though total debt stands at $948.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $236.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 26.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.31B (2022) to $2.71B (2025), reflecting a 107% increase over the period.
As with any equity investment, PODD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Insulet Corporation and its sector.